

# THE LANCET

## Rheumatology

### Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.  
We post it as supplied by the authors.

Supplement to: Kronzer VL, Hayashi K, Yoshida K, et al. Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case-control study. *Lancet Rheumatol* 2023; 5: e77-87.

# **Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: A nested case-control study**

## **Supplemental material:**

**Table S1.** Clinical characteristics of incident RA-ILD cases (n=84)

**Table S2.** Additional adjusted associations between autoantibodies to citrullinated antigens and incident RA-ILD

**Table S3.** Additional adjusted associations between autoantibodies to native antigens and incident RA-ILD

**Table S4.** All unadjusted associations between autoantibodies to citrullinated proteins and incident RA-ILD

**Table S5.** All unadjusted associations between autoantibodies to native proteins and incident RA-ILD

**Table S6.** All adjusted\* associations between autoantibodies to citrullinated proteins and incident UIP/fibrotic NSIP subtype of RA-ILD

**Table S7.** All adjusted\* associations between autoantibodies to native proteins and incident cellular NSIP subtype of RA-ILD

**Table S8.** All adjusted\* associations between autoantibodies to citrullinated proteins and incident fibrotic UIP subtype of RA-ILD

**Table S9.** All adjusted associations between autoantibodies to native proteins and incident fibrotic UIP subtype of RA-ILD

**Table S10.** All adjusted\* associations between autoantibodies to citrullinated proteins and incident RA-ILD among seropositive RA

**Table S11.** All adjusted\* associations between autoantibodies to native proteins and incident RA-ILD among seropositive RA

**Table S12.** All adjusted\* associations between autoantibodies to citrullinated proteins and incident RA-ILD among seronegative RA

**Table S13.** All adjusted\* associations between autoantibodies to native proteins and incident RA-ILD among seronegative RA

**Table S14.** All adjusted\* associations between autoantibodies to citrullinated proteins and incident RA-ILD among anti-CCP-positive RA

**Table S15.** All adjusted\* associations between autoantibodies to native proteins and incident RA-ILD among anti-CCP-positive RA

**Table S16.** All adjusted\* associations between autoantibodies to citrullinated proteins and incident RA-ILD among anti-CCP-negative RA

**Table S17.** All adjusted\* associations between autoantibodies to native proteins and incident incident RA-ILD among anti-CCP-negative RA

**Table S18.** All adjusted\* associations between autoantibodies after subtraction of results of native from citrullinated proteins and incident RA-ILD

**Figure S1.** Receiver operating characteristic curves for incident RA-ILD risk among 84 cases and 233 RA-noILD controls in BRASS, for 6 novel biomarkers

**Figure S2.** Receiver operating characteristic curves for incident RA-ILD risk among 84 cases and 233 RA-noILD controls in BRASS for novel biomarkers grouped as autoantibodies to citrullinated or native proteins

**Table S19.** Pairwise comparisons of AUCs between different models for incident RA-ILD risk

**Table S20.** Model coefficients and odds ratios used for RA-ILD risk score development

**Table S1. Clinical characteristics of incident RA-ILD cases (n=84)**

RA-ILD subtype, n (%)	n (%)
Cellular NSIP	44 (52.4)
UIP/Fibrotic NSIP	29 (34.5)
AIP/DAD/others	11 (13.1)
RA-ILD radiographic severity, n (%)	n (%)
Mild	17 (20.2)
Moderate/severe	67 (79.8)
Pulmonary function test results*, mean ± SD	Mean ± SD
FEV <sub>1</sub> % predicted, mean ± SD	73.0 ± 22.0
FVC % predicted, mean ± SD	76.9 ± 17.2
FEV <sub>1</sub> /FVC, mean ± SD	0.74 ± 0.11
TLC % predicted, mean ± SD	88.4 ± 19.5
DLco % predicted, mean ± SD	60.9 ± 20.6

\*Available on n=53 patients

AIP = acute interstitial pneumonia, DAD = diffuse alveolar damage, DLco = diffusing capacity for carbon monoxide, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, NSIP = non-specific interstitial pneumonia, RA-ILD = rheumatoid arthritis-associated interstitial lung disease, SD = standard deviation, TLC = total lung capacity

**Table S2. Additional adjusted associations between autoantibodies to citrullinated antigens and incident RA-ILD**

Targeted citrullinated antigen*	Adjusted** OR (95% CI)	FDR p-value
FibrinogenB 285-305 cit (IgG)	1.34 (0.97,1.86)	0.49
FibrinogenB 62-81 cit 74 (IgA1)	0.80 (0.62,1.03)	0.49
H4 33-48 cit 39 (IgG)	1.29 (0.97,1.73)	0.49
Biglycan 247-266 cit cyclic (IgA1)	0.80 (0.58,1.09)	0.73
H2A/a-2 1-20 cit (IgA1)	0.81 (0.60,1.09)	0.73
FibrinogenA 41-60 cit3 cyclic (IgA2)	1.84 (0.77,4.39)	0.73
FibrinogenB 62-81 cit 72 (IgA1)	0.83 (0.64,1.09)	0.73
H2B/a 62-81 cit cyclic (IgG)	0.81 (0.59,1.11)	0.73
Vimentin 58-77 cit3 cyclic (IgA1)	0.83 (0.63,1.10)	0.73
FibrinogenA 27-43 cit (IgA2)	0.77 (0.50,1.17)	0.73
H2A/a 1-20 cit cyclic (IgA1)	0.85 (0.66,1.10)	0.73
Vimentin 58-77 cit3 cyclic (IgA2)	1.42 (0.81,2.49)	0.73
Biglycan 247-266 cit cyclic (IgA2)	0.63 (0.28,1.39)	0.73
Collagen Type II 281-298 cit 290 (IgA1)	0.84 (0.62,1.14)	0.73
H2B/a 62-81 cit cyclic (IgA1)	0.82 (0.58,1.16)	0.73
B-actin 191-216 cit 196.206.210 (IgG)	1.18 (0.88,1.59)	0.73
FibrinogenB 54-74 cit 60 72 74 (IgA1)	0.83 (0.60,1.16)	0.73
Clusterin 221-240 cit cyclic (IgA1)	0.85 (0.64,1.14)	0.73
FibrinogenA 616-635 cit3 cyclic (IgA1)	0.87 (0.67,1.12)	0.73
FibrinogenA 563-583 cit 573 (IgA2)	1.26 (0.83,1.90)	0.73
Enolase-1A 5-21 cit (IgA2)	1.27 (0.82,1.98)	0.73
Fibronectin cit 1035 1036 (IgA2)	1.15 (0.87,1.52)	0.78
FibrinogenA 27-43 cit (IgA1)	0.88 (0.67,1.15)	0.78
FibrinogenB 54-74 cit 60 72 74(IgG)	1.18 (0.83,1.68)	0.78
FibrinogenB 246-267 cit (IgG)	1.16 (0.84,1.61)	0.78
Vimentin 1-16 cit (IgA1)	0.86 (0.60,1.22)	0.78
H4 33-48 cit 39 40 (IgA1)	1.09 (0.90,1.33)	0.78
Enolase-1A 5-21 cit (IgA1)	0.90 (0.71,1.15)	0.78
FibrinogenA 211-230 cit cyclic (IgG)	0.85 (0.58,1.25)	0.78
FibrinogenB 285-305 cit (IgA1)	0.86 (0.61,1.22)	0.78
FibrinogenB 285-305 cit (IgA2)	0.81 (0.48,1.36)	0.78
B-actin 191-216 cit 196.206.210 (IgA2)	1.18 (0.79,1.77)	0.78
FibrinogenB 62-81 cit 72 (IgA2)	0.84 (0.55,1.30)	0.78
FibrinogenB 62-81 cit 74 (IgG)	0.89 (0.66,1.20)	0.78
Clusterin 221-240 cit cyclic (IgA2)	1.26 (0.68,2.33)	0.82
FibrinogenB 36-52 cit (IgG)	0.87 (0.60,1.28)	0.82
FibrinogenB 62-81 cit 72 (IgG)	0.90 (0.65,1.25)	0.89
Collagen Type II 281-298 cit 290 (IgG)	0.90 (0.63,1.28)	0.90
FibrinogenB 246-267 cit (IgA1)	0.90 (0.62,1.30)	0.92
H2B/a 62-81 cit cyclic (IgA2)	0.69 (0.17,2.72)	0.92
FibrinogenB 246-267 cit (IgA2)	0.86 (0.44,1.67)	0.96
FibrinogenA 563-583 cit 573 (IgG)	1.07 (0.80,1.43)	0.96
FibrinogenB 54-74 cit 60 72 74 (IgA2)	1.19 (0.56,2.52)	0.96
H4 33-48 cit 39 (IgA1)	1.07 (0.79,1.44)	0.96
Vimentin 58-77 cit3 cyclic (IgG)	0.94 (0.71,1.26)	0.97
FibrinogenB 62-81 cit 74 (IgA2)	0.91 (0.58,1.44)	0.97
Fibronectin cit 1035 1036 (IgA1)	1.03 (0.84,1.27)	0.98

FibrinogenA 616-635 cit3 cyclic (IgG)	0.96 (0.69,1.33)	0.98
Clusterin 231-250 cit cyclic (IgA2)	0.97 (0.78,1.21)	0.98
Collagen Type II 281-298 cit 290 (IgA2)	0.94 (0.55,1.61)	0.98
FibrinogenA 616-635 cit3 cyclic (IgA2)	1.05 (0.68,1.61)	0.98
Vimentin 1-16 cit (IgG)	0.96 (0.66,1.40)	0.98
Vimentin 1-16 cit (IgA2)	0.89 (0.25,3.10)	0.98
B-actin 191-216 cit 196.206.210 (IgA1)	1.03 (0.79,1.34)	0.98
Biglycan 247-266 cit cyclic (IgG)	1.03 (0.74,1.43)	0.98
H2A/a-2 1-20 cit (IgG)	1.03 (0.72,1.48)	0.98
FibrinogenA 211-230 cit cyclic (IgA1)	0.98 (0.73,1.31)	0.98
FibrinogenA 41-60 cit3 cyclic (IgA1)	0.98 (0.73,1.32)	0.98
FibrinogenB 36-52 cit (IgA1)	0.98 (0.71,1.35)	0.98
Enolase-1A 5-21 cit (IgG)	0.99 (0.78,1.25)	0.98
Clusterin 221-240 cit cyclic (IgG)	1.02 (0.76,1.36)	0.98
H4 33-48 cit 39 40 (IgA2)	1.01 (0.78,1.31)	0.98
Clusterin 231-250 cit cyclic (IgA1)	0.99 (0.81,1.21)	0.98
FibrinogenA 27-43 cit (IgG)	0.99 (0.75,1.30)	0.98
H2A/a 1-20 cit cyclic (IgG)	1.01 (0.75,1.36)	0.98
FibrinogenA 211-230 cit cyclic (IgA2)	0.98 (0.48,2.01)	0.98
FibrinogenA 563-583 cit 573 (IgA1)	1.0 (0.78,1.29)	0.99
FibrinogenA 41-60 cit3 cyclic (IgG)	1.0 (0.68,1.48)	0.99

BMI = body mass index, CI = confidence interval, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Presented by level of significance.

\*\*Per log-transformed unit. Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S3. Additional adjusted associations between autoantibodies to native antigens and incident RA-ILD**

Targeted native antigen*	Adjusted** OR (95% CI)	FDR p-value
FibrinogenB 62-81 (IgA1)	0.81 (0.61,1.09)	0.57
H2A/a-2 1-20 (IgA1)	1.21 (0.88,1.66)	0.72
tenascin C 5 (IgG)	0.81 (0.57,1.16)	0.72
H2A/a 1-20 cyclic (IgA1)	1.20 (0.87,1.66)	0.72
tenascin C 5 (IgA1)	0.82 (0.58,1.18)	0.72
Filaggrin 48-65 cyclic (IgA1)	1.35 (0.77,2.37)	0.72
FibrinogenB 285-305 (IgG)	0.84 (0.58,1.24)	0.78
FibrinogenB 285-305 (IgA1)	0.86 (0.60,1.22)	0.78
Vimentin 58-77 cyclic (IgA1)	1.15 (0.84,1.58)	0.78
FibrinogenB 54-74 (IgA1)	0.88 (0.65,1.19)	0.78
FibrinogenB 62-81 (IgA2)	0.80 (0.44,1.45)	0.79
Vimentin 265-278 (IgG)	0.88 (0.61,1.27)	0.79
FibrinogenB 54-74 (IgG)	0.88 (0.60,1.29)	0.79
Collagen Type II 281-298 (IgA1)	0.90 (0.65,1.24)	0.79
FibrinogenB 54-74 (IgA2)	0.84 (0.48,1.46)	0.79
Filaggrin 48-65 cyclic (IgA2)	0.67 (0.19,2.38)	0.79
H2B/a 62-81 cyclic (IgG)	0.90 (0.64,1.28)	0.79
Collagen Type II 281-298 (IgG)	0.90 (0.62,1.30)	0.79
Vimentin 1-16 (IgA2)	0.83 (0.41,1.69)	0.80
Vimentin 1-16 (IgA1)	0.92 (0.67,1.27)	0.80
H2B/a 62-81 cyclic (IgA1)	0.93 (0.67,1.29)	0.80
Vimentin 265-278 (IgA1)	0.93 (0.67,1.29)	0.80
Vimentin 265-278 (IgA2)	0.91 (0.46,1.79)	0.93
Collagen Type II 281-298 (IgA2)	0.93 (0.49,1.75)	0.94
FibrinogenB 62-81 (IgG)	1.03 (0.74,1.43)	0.94
Vimentin 1-16 (IgG)	1.03 (0.69,1.54)	0.94
H2B/a 62-81 cyclic (IgA2)	1.04 (0.57,1.89)	0.94
tenascin C 5 (IgA2)	0.95 (0.38,2.41)	0.94
FibrinogenB 285-305 (IgA2)	0.99 (0.48,2.03)	0.98

BMI = body mass index, CI = confidence interval, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Presented by level of significance.

\*\*Per log-transformed unit. Adjusting for significant covariates including BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S4. All unadjusted associations between autoantibodies to citrullinated proteins and incident RA-ILD**

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
H4 33-48 cit 39 (IgA2)	0.090	0.038	0.212	<0.0001	<0.0001
H2A/a-2 1-20 cit (IgA2)	4.406	2.323	8.359	<0.0001	0.0002
Filaggrin 48-65 cit2 cyclic (IgG)	3.469	1.806	6.662	0.0002	0.0049
Clusterin 231-250 cit cyclic (IgG)	1.350	1.148	1.589	0.0003	0.0056
H4 33-48 cit 39 40 (IgG)	1.262	1.080	1.474	0.0033	0.0521
H2A/a 1-20 cit cyclic (IgA2)	1.790	1.197	2.677	0.0046	0.0596
Filaggrin 48-65 cit2 cyclic (IgA2)	4.959	1.448	16.992	0.0108	0.1205
Fibronectin cit 1035 1036 (IgG)	1.210	1.038	1.412	0.0150	0.1459
Vimentin 58-77 cit3 cyclic (IgA2)	1.822	1.106	3.003	0.0185	0.1607
Enolase-1A 5-21 cit (IgA2)	1.497	1.036	2.162	0.0318	0.2477
Filaggrin 48-65 cit2 cyclic (IgA1)	1.756	1.028	3.001	0.0393	0.2788
Clusterin 221-240 cit cyclic (IgA2)	1.596	1.000	2.547	0.0500	0.3091
H4 33-48 cit 39 (IgG)	1.241	0.998	1.544	0.0523	0.3091
H4 33-48 cit 39 40 (IgA1)	1.161	0.997	1.353	0.0555	0.3091
FibrinogenB 285-305 cit(IgA2)	0.667	0.437	1.017	0.0597	0.3106
Clusterin 231-250 cit cyclic (IgA2)	1.169	0.990	1.381	0.0653	0.3181
FibrinogenB 285-305 cit(IgA1)	0.780	0.591	1.030	0.0799	0.3470
FibrinogenB 36-52 cit (IgA2)	0.445	0.180	1.102	0.0801	0.3470
Enolase-1A 5-21 cit (IgG)	1.179	0.974	1.427	0.0903	0.3670
Clusterin 231-250 cit cyclic (IgA1)	1.147	0.977	1.347	0.0941	0.3670
FibrinogenB 246-267 cit (IgA1)	0.786	0.586	1.055	0.1087	0.4017
Fibronectin cit 1035 1036 (IgA2)	1.185	0.960	1.463	0.1136	0.4017
FibrinogenA 211-230 cit cyclic (IgG)	0.775	0.560	1.074	0.1256	0.4017
FibrinogenB 54-74 cit 60 72 74 (IgA1)	0.811	0.619	1.062	0.1277	0.4017
FibrinogenB 62-81 cit 74 (IgA1)	0.849	0.687	1.049	0.1288	0.4017
Collagen Type II 281-298 cit 290 (IgG)	0.805	0.605	1.070	0.1345	0.4036
FibrinogenB 36-52 cit (IgG)	0.802	0.587	1.096	0.1670	0.4825
H4 33-48 cit 39 (IgA1)	1.163	0.929	1.456	0.1882	0.5135
FibrinogenA 563-583 cit 573 (IgA2)	1.219	0.906	1.640	0.1920	0.5135
FibrinogenB 285-305 (IgG)	1.175	0.920	1.500	0.1975	0.5135
FibrinogenB 246-267 cit (IgA2)	0.727	0.439	1.204	0.2160	0.5435
FibrinogenA 41-60 cit3 cyclic (IgA2)	1.500	0.760	2.962	0.2427	0.5864
H2B/a 62-81 cit cyclic (IgA1)	0.849	0.642	1.123	0.2511	0.5864
Vimentin 1-16 cit (IgG)	0.841	0.622	1.135	0.2574	0.5864
FibrinogenA 616-635 cit3 cyclic (IgA2)	1.207	0.863	1.687	0.2711	0.5864
Biglycan 247-266 cit cyclic (IgA1)	0.868	0.674	1.118	0.2740	0.5864
Collagen Type II 281-298 cit 290 (IgA1)	0.869	0.675	1.120	0.2782	0.5864
H2B/a 62-81 cit cyclic (IgG)	0.866	0.662	1.133	0.2934	0.5963
Fibronectin cit 1035 1036 (IgA1)	1.093	0.924	1.294	0.2981	0.5963

Clusterin 221-240 cit cyclic (IgG)	1.119	0.886	1.414	0.3456	0.6739
FibrinogenB 62-81 cit 72 (IgG)	0.885	0.681	1.149	0.3585	0.6819
Vimentin 1-16 cit (IgA1)	0.883	0.661	1.180	0.4011	0.7449
FibrinogenB 62-81 cit 72 (IgA1)	0.912	0.731	1.138	0.4169	0.7485
H2A/a-2 1-20 cit (IgA1)	0.903	0.702	1.161	0.4256	0.7485
FibrinogenA 27-43 cit (IgG)	1.090	0.879	1.353	0.4318	0.7485
Vimentin 1-16 cit (IgA2)	0.691	0.248	1.922	0.4790	0.8122
B-actin 191-216 cit 196.206.210 (IgA1)	0.928	0.750	1.148	0.4911	0.8150
Vimentin 58-77 cit3 cyclic (IgG)	1.077	0.855	1.355	0.5285	0.8289
FibrinogenB 36-52 cit (IgA1)	0.925	0.720	1.187	0.5400	0.8289
Vimentin 58-77 cit3 cyclic (IgA1)	0.933	0.737	1.181	0.5648	0.8289
FibrinogenA 616-635 cit3 cyclic (IgA1)	0.936	0.748	1.172	0.5662	0.8289
FibrinogenB 62-81 cit 72 (IgA2)	0.909	0.643	1.285	0.5895	0.8289
Collagen Type II 281-298 cit 290 (IgA2)	0.890	0.579	1.370	0.5971	0.8289
Clusterin 221-240 cit cyclic (IgA1)	0.938	0.735	1.197	0.6071	0.8289
H2A/a 1-20 cit cyclic (IgA1)	0.945	0.761	1.174	0.6085	0.8289
Enolase-1A 5-21 cit (IgA1)	1.053	0.863	1.285	0.6098	0.8289
FibrinogenB 62-81 cit 74 (IgG)	0.941	0.744	1.189	0.6100	0.8289
FibrinogenA 27-43 cit (IgA1)	0.944	0.752	1.186	0.6223	0.8289
H4 33-48 cit 39 40 (IgA2)	1.049	0.864	1.273	0.6270	0.8289
Biglycan 247-266 cit cyclic (IgA2)	0.867	0.470	1.597	0.6464	0.8307
H2A/a 1-20 cit cyclic (IgG)	1.055	0.838	1.326	0.6496	0.8307
H2A/a-2 1-20 cit (IgG)	1.054	0.806	1.378	0.6997	0.8597
Biglycan 247-266 cit cyclic (IgG)	1.053	0.808	1.373	0.7037	0.8597
H2B/a 62-81 cit cyclic (IgA2)	0.812	0.276	2.390	0.7054	0.8597
FibrinogenA 41-60 cit3 cyclic (IgG)	0.944	0.685	1.301	0.7242	0.8691
B-actin 191-216 cit 196.206.210 (IgG)	1.038	0.824	1.306	0.7531	0.8900
FibrinogenB 62-81 cit 74 (IgA2)	0.949	0.669	1.346	0.7691	0.8927
FibrinogenB 52-74 cit 60 72 74 (IgG)	1.042	0.783	1.386	0.7782	0.8927
FibrinogenA 563-583 cit 573 (IgA1)	1.027	0.839	1.257	0.7973	0.9012
FibrinogenA 211-230 cit cyclic (IgA2)	0.941	0.492	1.800	0.8540	0.9434
FibrinogenB 246-267 cit (IgG)	1.022	0.792	1.320	0.8653	0.9434
FibrinogenA 41-60 cit3 cyclic (IgA1)	0.979	0.763	1.257	0.8708	0.9434
FibrinogenA 27-43 cit (IgA2)	1.019	0.737	1.408	0.9117	0.9656
FibrinogenA 211-230 cit cyclic (IgA1)	0.986	0.766	1.271	0.9161	0.9656
FibrinogenA 563-583 cit 573 (IgG)	1.009	0.805	1.265	0.9364	0.9694
FibrinogenB 54-74 cit 60 72 74 (IgA2)	1.023	0.544	1.921	0.9445	0.9694
B-actin 191-216 cit 196.206.210 (IgA2)	0.993	0.714	1.382	0.9678	0.9804
FibrinogenA 616-635 cit3 cyclic (IgG)	1.002	0.776	1.293	0.9894	0.9894

cit = citrullinated, CL = confidence limit, OR = odds ratio.

**Table S5. All unadjusted associations between autoantibodies to native proteins and incident RA-ILD**

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
H2A/a 1-20 cyclic (IgA2)	12.345	3.483	43.756	<0.0001	0.0039
H2A/a-2 1-20 (IgA2)	7.457	2.459	22.611	0.0004	0.0075
Filaggrin 48-65 cyclic (IgG)	3.472	1.588	7.595	0.0018	0.0237
H2A/a 1-20 cyclic (IgG)	2.233	1.238	4.029	0.0076	0.0744
H2A/a-2 1-20 (IgG)	2.106	1.180	3.758	0.0117	0.0913
H2A/a-2 1-20 (IgA1)	1.461	0.974	2.191	0.0667	0.4334
FibrinogenB 62-81 (IgA1)	0.733	0.516	1.041	0.0823	0.4587
Vimentin 58-77 cyclic (IgA2)	2.015	0.880	4.615	0.0976	0.4756
Vimentin 58-77 cyclic (IgG)	1.411	0.915	2.175	0.1191	0.5004
tenascin C 5 (IgA1)	0.719	0.466	1.107	0.1341	0.5004
tenascin C 5 (IgG)	0.715	0.457	1.118	0.1411	0.5004
Collagen Type II 281-298 (IgG)	0.717	0.453	1.134	0.1545	0.5020
H2A/a 1-20 cyclic (IgA1)	1.309	0.893	1.917	0.1675	0.5026
Collagen Type II 281-298 (IgA1)	0.773	0.517	1.155	0.2082	0.5800
tenascin C 1 (IgA1)	0.807	0.567	1.149	0.2347	0.6102
FibrinogenB 285-305 (IgG)	0.781	0.486	1.256	0.3079	0.6915
Vimentin 1-16 (IgA1)	0.819	0.553	1.213	0.3195	0.6915
FibrinogenB 285-305 (IgA1)	0.809	0.524	1.247	0.3363	0.6915
Vimentin 265-278 (IgA1)	0.819	0.540	1.243	0.3487	0.6915
Filaggrin 48-65 cyclic (IgA1)	1.357	0.700	2.634	0.3662	0.6915
FibrinogenB 54-74 (IgA1)	0.862	0.604	1.230	0.4124	0.6915
H2B/a 62-81 cyclic (IgA2)	1.315	0.683	2.531	0.4124	0.6915
tenascin C 5 (IgA2)	0.624	0.200	1.953	0.4183	0.6915
H2B/a 62-81 cyclic (IgG)	0.831	0.527	1.311	0.4255	0.6915
Vimentin 58-77 cyclic (IgA1)	1.141	0.795	1.640	0.4743	0.6947
Vimentin 265-278 (IgG)	0.856	0.558	1.315	0.4777	0.6947
FibrinogenB 54-74 (IgG)	0.846	0.532	1.346	0.4809	0.6947
tenascin C 1 (IgG)	0.871	0.573	1.325	0.5181	0.7217
FibrinogenB 285-305 (IgA2)	1.235	0.556	2.742	0.6044	0.8128
Vimentin 1-16 (IgG)	0.902	0.553	1.471	0.6798	0.8837
FibrinogenB 62-81 (IgA2)	0.897	0.494	1.632	0.7229	0.9095
Vimentin 1-16 (IgA2)	0.909	0.413	2.002	0.8128	0.9279
Filaggrin 48-65 cyclic (IgA2)	0.847	0.214	3.355	0.8134	0.9279
H2B/a 62-81 cyclic (IgA1)	0.963	0.650	1.428	0.8515	0.9279
Vimentin 265-278 (IgA2)	0.938	0.435	2.021	0.8698	0.9279
tenascin C 1 (IgA2)	1.068	0.462	2.467	0.8785	0.9279
FibrinogenB 62-81 (IgG)	0.971	0.664	1.420	0.8803	0.9279
FibrinogenB 54-74 (IgA2)	1.029	0.590	1.795	0.9200	0.9442
Collagen Type II 281-298 (IgA2)	0.988	0.488	2.002	0.9741	0.9741

CL = confidence limit, OR = odds ratio.

**Table S6. All adjusted\* associations between autoantibodies to citrullinated proteins and incident cellular NSIP subtype of RA-ILD**

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
H2A/a-2 1-20 cit (IgA2)	10.939	3.011	39.741	0.0003	0.0217
Filaggrin 48-65 cit2 cyclic (IgG)	22.712	2.417	213.400	0.0063	0.1798
H4 33-48 cit 39 (IgA2)	0.140	0.034	0.583	0.0069	0.1798
FibrinogenB 62-81 cit 74 (IgA1)	0.597	0.391	0.911	0.0168	0.3280
H2A/a 1-20 cit cyclic (IgA2)	2.777	1.158	6.657	0.0221	0.3441
Biglycan 247-266 cit cyclic (IgA1)	0.511	0.271	0.963	0.0379	0.4747
Filaggrin 48-65 cit2 cyclic (IgA1)	3.287	0.986	10.956	0.0527	0.4747
FibrinogenA 616-635 cit3 cyclic (IgA1)	0.641	0.408	1.007	0.0537	0.4747
Vimentin 58-77 cit3 cyclic (IgA2)	3.448	0.873	13.621	0.0774	0.4747
Collagen Type II 281-298 cit 290 (IgA1)	0.638	0.386	1.053	0.0785	0.4747
Clusterin 221-240 cit cyclic (IgA1)	0.598	0.337	1.061	0.0790	0.4747
FibrinogenB 54-74 60 72 74 cit (IgA1)	0.593	0.330	1.065	0.0802	0.4747
Filaggrin 48-65 cit2 cyclic (IgA2)	8.251	0.761	89.402	0.0826	0.4747
FibrinogenB 285-305 cit (IgG)	1.817	0.921	3.587	0.0852	0.4747
FibrinogenB 62-81 cit 72 (IgA1)	0.698	0.458	1.064	0.0949	0.4933
Enolase-1A 5-21 cit (IgA1)	0.685	0.434	1.082	0.1045	0.5094
H2B/a 62-81 cit cyclic (IgA1)	0.566	0.270	1.187	0.1321	0.6061
Vimentin 1-16 cit (IgA1)	0.636	0.332	1.218	0.1726	0.7480
B-actin 191-216 cit 196.206.210 (IgG)	1.387	0.844	2.279	0.1971	0.7688
FibrinogenA 41-60 cit3 cyclic (IgA2)	2.613	0.607	11.245	0.1971	0.7688
FibrinogenA 563-583 cit 573 (IgA2)	1.544	0.759	3.143	0.2310	0.8263
Fibronectin cit 1035 1036 (IgG)	1.219	0.872	1.702	0.2462	0.8263
Fibronectin cit 1035 1036 (IgA2)	1.264	0.849	1.882	0.2494	0.8263
Vimentin 58-77 cit3 cyclic (IgA1)	0.740	0.433	1.266	0.2718	0.8263
FibrinogenB 54-74 cit 60 72 74 (IgG)	1.374	0.767	2.462	0.2858	0.8263
FibrinogenB 246-267 cit (IgG)	1.364	0.741	2.511	0.3188	0.8263
FibrinogenA 616-635 cit3 cyclic (IgA2)	0.678	0.310	1.483	0.3308	0.8263
FibrinogenA 27-43 cit (IgA1)	0.769	0.451	1.311	0.3338	0.8263
FibrinogenA 563-583 cit 573 (IgA1)	0.807	0.518	1.257	0.3431	0.8263
Vimentin 1-16 cit (IgA2)	0.274	0.018	4.076	0.3470	0.8263
H4 33-48 cit 39 40 (IgG)	1.150	0.852	1.552	0.3605	0.8263
H4 33-48 cit 39 40 (IgA2)	1.153	0.844	1.574	0.3703	0.8263
H2A/a 1-20 cit cyclic (IgA1)	0.810	0.510	1.288	0.3737	0.8263
B-actin 191-216 cit 196.206.210 (IgA2)	1.256	0.757	2.084	0.3784	0.8263
H2B/a 62-81 cit cyclic (IgG)	0.793	0.472	1.330	0.3786	0.8263
Enolase-1A 5-21 cit (IgA2)	1.289	0.727	2.284	0.3843	0.8263
FibrinogenB 285-305 (IgA1)	0.789	0.454	1.371	0.4005	0.8263

Clusterin 231-250 cit cyclic (IgG)	1.148	0.831	1.585	0.4026	0.8263
FibrinogenB 62-81 cit 74 (IgG)	0.823	0.515	1.314	0.4139	0.8278
H4 33-48 cit 39 (IgG)	1.198	0.762	1.883	0.4334	0.8281
FibrinogenA 616-635 cit3 cyclic (IgG)	0.792	0.440	1.424	0.4353	0.8281
Clusterin 231-250 cit cyclic (IgA1)	0.869	0.603	1.252	0.4518	0.8391
FibrinogenA 211-230 cit cyclic (IgA2)	1.422	0.537	3.763	0.4784	0.8678
Biglycan 247-266 cit cyclic (IgG)	0.852	0.526	1.381	0.5163	0.9152
FibrinogenA 27-43 cit (IgA2)	0.732	0.262	2.045	0.5516	0.9446
H2A/a-2 1-20 cit (IgA1)	0.862	0.510	1.455	0.5776	0.9446
FibrinogenB 62-81 cit 72 (IgA2)	0.860	0.481	1.538	0.6119	0.9446
FibrinogenB 62-81 cit 74 (IgA2)	0.863	0.481	1.550	0.6219	0.9446
Biglycan 247-266 cit cyclic (IgA2)	0.740	0.221	2.478	0.6251	0.9446
FibrinogenA 41-60 cit3 cyclic (IgG)	1.152	0.649	2.044	0.6293	0.9446
Vimentin 1-16 cit (IgG)	1.150	0.652	2.027	0.6295	0.9446
Clusterin 221-240 cit cyclic (IgA2)	1.229	0.531	2.843	0.6297	0.9446
Collagen Type II 281-298 cit 290 (IgA2)	0.861	0.414	1.794	0.6904	0.9558
FibrinogenA 211-230 cit cyclic (IgG)	0.887	0.486	1.622	0.6977	0.9558
FibrinogenA 41-60 cit3 cyclic (IgA1)	0.903	0.538	1.514	0.6984	0.9558
Enolase-1A 5-21 cit (IgG)	0.936	0.634	1.381	0.7395	0.9558
FibrinogenA 27-43 cit (IgG)	1.076	0.660	1.755	0.7682	0.9558
Vimentin 58-77 cit3 cyclic (IgG)	1.059	0.706	1.589	0.7805	0.9558
FibrinogenB 285-305 cit (IgA2)	0.912	0.467	1.781	0.7879	0.9558
FibrinogenA 211-230 cit cyclic (IgA1)	0.940	0.599	1.476	0.7884	0.9558
Clusterin 221-240 cit cyclic (IgG)	0.945	0.613	1.454	0.7956	0.9558
FibrinogenA 563-583 cit 573 (IgG)	1.061	0.669	1.682	0.8010	0.9558
Collagen Type II 281-298 cit 290 (IgG)	0.940	0.568	1.556	0.8092	0.9558
FibrinogenB 36-52 cit (IgA2)	0.849	0.192	3.746	0.8285	0.9558
FibrinogenB 246-267 cit (IgA2)	0.911	0.367	2.261	0.8408	0.9558
FibrinogenB 62-81 cit 72 (IgG)	0.950	0.561	1.608	0.8484	0.9558
H2A/a-2 1-20 cit (IgG)	0.952	0.571	1.589	0.8518	0.9558
H4 33-48 cit 39 (IgA1)	0.959	0.608	1.512	0.8572	0.9558
FibrinogenB 246-267 cit (IgA1)	0.947	0.510	1.758	0.8625	0.9558
Clusterin 231-250 cit cyclic (IgA2)	1.025	0.759	1.384	0.8719	0.9558
B-actin 191-216 cit 196.206.210 (IgA1)	1.029	0.698	1.517	0.8858	0.9558
H2A/a 1-20 cit cyclic (IgG)	0.972	0.634	1.491	0.8972	0.9558
FibrinogenB 36-52 cit (IgA1)	0.968	0.577	1.624	0.9005	0.9558
FibrinogenB 36-52 cit (IgG)	0.970	0.576	1.634	0.9099	0.9558
FibrinogenB 54-74 cit 60 72 74 (IgA2)	0.957	0.338	2.706	0.9334	0.9558
H4 33-48 cit 39 40 (IgA1)	1.011	0.759	1.347	0.9400	0.9558
Fibronectin cit 1035 1036 (IgA1)	1.011	0.740	1.383	0.9436	0.9558
H2B/a 62-81 cit cyclic (IgA2)	0.938	0.080	10.962	0.9596	0.9596

Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S7. All adjusted\* associations between autoantibodies to native proteins and incident cellular NSIP subtype of RA-ILD**

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
H2A/a 1-20 cyclic (IgA2)	50.247	6.923	364.701	0.0001	0.0034
H2A/a-2 1-20 (IgA2)	16.755	3.850	72.908	0.0002	0.0034
Filaggrin 48-65 cyclic (IgG)	5.903	1.590	21.921	0.0080	0.1039
H2A/a 1-20 cyclic (IgG)	3.307	1.239	8.825	0.0169	0.1652
H2A/a-2 1-20 (IgG)	3.104	1.172	8.225	0.0227	0.1770
Vimentin 58-77 cyclic (IgG)	2.043	1.005	4.155	0.0485	0.3154
Vimentin 58-77 cyclic (IgA2)	3.123	0.848	11.506	0.0869	0.4759
H2A/a-2 1-20 (IgA1)	1.642	0.913	2.953	0.0976	0.4759
tenascin C 1 (IgA1)	0.681	0.423	1.097	0.1140	0.4941
FibrinogenB 62-81 (IgA1)	0.729	0.475	1.120	0.1495	0.5832
H2A/a 1-20 cyclic (IgA1)	1.473	0.826	2.625	0.1896	0.6583
tenascin C 5 (IgA1)	0.652	0.338	1.259	0.2025	0.6583
Collagen Type II 281-298 (IgA1)	0.719	0.422	1.223	0.2235	0.6706
FibrinogenB 54-74 (IgA1)	0.761	0.474	1.221	0.2571	0.7009
FibrinogenB 285-305 (IgA1)	0.709	0.385	1.306	0.2696	0.7009
Vimentin 58-77 cyclic (IgA1)	1.287	0.785	2.110	0.3171	0.7730
Filaggrin 48-65 cyclic (IgA1)	1.555	0.623	3.881	0.3446	0.7886
Vimentin 265-278 (IgA1)	0.776	0.447	1.350	0.3698	0.7886
Vimentin 1-16 (IgA1)	0.798	0.475	1.341	0.3947	0.7886
H2B/a 62-81 cyclic (IgA1)	0.789	0.452	1.377	0.4044	0.7886
tenascin C 5 (IgA2)	0.546	0.102	2.929	0.4797	0.8910
tenascin C 5 (IgG)	0.819	0.439	1.527	0.5296	0.9294
FibrinogenB 62-81 (IgG)	1.136	0.677	1.907	0.6283	0.9294
tenascin C 1 (IgA2)	0.758	0.244	2.357	0.6327	0.9294
Vimentin 1-16 (IgG)	1.166	0.614	2.217	0.6383	0.9294
tenascin C 1 (IgG)	0.896	0.536	1.497	0.6746	0.9294
Vimentin 265-278 (IgG)	0.888	0.500	1.577	0.6843	0.9294
Collagen Type II 281-298 (IgA2)	0.871	0.384	1.975	0.7411	0.9294
Filaggrin 48-65 cyclic (IgA2)	0.755	0.115	4.977	0.7706	0.9294
H2B/a 62-81 cyclic (IgG)	1.076	0.607	1.908	0.8012	0.9294
Vimentin 265-278 (IgA2)	0.892	0.364	2.188	0.8027	0.9294
H2B/a 62-81 cyclic (IgA2)	1.067	0.469	2.430	0.8771	0.9294
FibrinogenB 285-305 (IgA2)	1.075	0.400	2.883	0.8864	0.9294
Vimentin 1-16 (IgA2)	0.939	0.379	2.326	0.8913	0.9294
FibrinogenB 54-74 (IgG)	1.037	0.581	1.850	0.9023	0.9294
FibrinogenB 54-74 (IgA2)	0.958	0.468	1.960	0.9060	0.9294
FibrinogenB 62-81 (IgA2)	0.959	0.454	2.026	0.9121	0.9294
Collagen Type II 281-298 (IgG)	0.973	0.557	1.701	0.9233	0.9294
FibrinogenB 285-305 (IgG)	0.972	0.524	1.805	0.9294	0.9294

Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S8. All adjusted\* associations between autoantibodies to citrullinated proteins and incident UIP/fibrotic NSIP subtype of RA-ILD**

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
FibrinogenA 211-230 cit cyclic (IgA2)	0.005	<0.001	0.313	0.0123	0.5045
FibrinogenB 36-52 cit (IgA2)	<0.001	<0.001	0.247	0.0167	0.5045
Biglycan 247-266 cit cyclic (IgA2)	0.112	0.015	0.871	0.0364	0.5045
H4 33-48 cit 39 (IgA2)	<0.001	<0.001	0.916	0.0475	0.5045
H2A/a-2 1-20 cit (IgA1)	0.500	0.246	1.014	0.0547	0.5045
Clusterin 231-250 cit cyclic (IgG)	1.691	0.988	2.894	0.0552	0.5045
Filaggrin 48-65 cit2 cyclic (IgA2)	18.564	0.883	390.260	0.0601	0.5045
H2B/a 62-81 cit cyclic (IgA1)	0.384	0.139	1.066	0.0661	0.5045
FibrinogenB 285-305 cit (IgA2)	0.142	0.017	1.162	0.0688	0.5045
H2A/a-2 1-20 cit (IgA2)	4.653	0.880	24.598	0.0703	0.5045
H4 33-48 cit 39 40 (IgG)	1.551	0.963	2.500	0.0711	0.5045
H4 33-48 cit 39 (IgG)	1.766	0.894	3.486	0.1014	0.5491
FibrinogenB 62-81 cit 74 (IgA1)	0.541	0.256	1.145	0.1083	0.5491
Collagen Type II 281-298 cit 290 (IgA2)	0.207	0.029	1.469	0.1151	0.5491
FibrinogenA 616-635 cit3 cyclic (IgA1)	0.510	0.220	1.179	0.1154	0.5491
FibrinogenA 211-230 cit cyclic (IgA1)	0.482	0.190	1.219	0.1231	0.5491
FibrinogenB 62-81 cit 74 (IgA2)	0.317	0.072	1.401	0.1298	0.5491
FibrinogenB 54-74 cit 60 72 74 (IgA1)	0.515	0.213	1.241	0.1392	0.5491
FibrinogenB 246-267 cit (IgA2)	0.177	0.017	1.861	0.1491	0.5491
FibrinogenA 211-230 cit cyclic (IgG)	0.560	0.253	1.241	0.1535	0.5491
Enolase-1A 5-21 cit (IgA1)	0.659	0.368	1.181	0.1615	0.5491
FibrinogenB 62-81 cit 72 (IgA2)	0.454	0.148	1.387	0.1655	0.5491
FibrinogenB 36-52 cit (IgG)	0.575	0.261	1.267	0.1698	0.5491
H4 33-48 cit 39 40 (IgA2)	0.597	0.277	1.288	0.1890	0.5491
FibrinogenB 285-305 cit (IgA1)	0.490	0.169	1.423	0.1895	0.5491
Collagen Type II 281-298 cit 290 (IgA1)	0.534	0.205	1.385	0.1970	0.5491
FibrinogenB 246-267 cit (IgA1)	0.498	0.171	1.447	0.2004	0.5491
Vimentin 58-77 cit3 cyclic (IgA1)	0.664	0.354	1.243	0.2007	0.5491
FibrinogenA 41-60 cit3 cyclic (IgG)	0.570	0.239	1.358	0.2041	0.5491
H2A/a 1-20 cit cyclic (IgA1)	0.733	0.442	1.216	0.2288	0.5727
H2B/a 62-81 cit cyclic (IgG)	0.714	0.413	1.236	0.2290	0.5727
FibrinogenA 27-43 cit (IgA1)	0.712	0.399	1.273	0.2521	0.5727
Filaggrin 48-65 cit2 cyclic (IgG)	1.558	0.728	3.337	0.2535	0.5727
Fibronectin cit 1035 1036 (IgA1)	0.725	0.416	1.263	0.2561	0.5727
Biglycan 247-266 cit cyclic (IgA1)	0.678	0.345	1.336	0.2616	0.5727
FibrinogenB 62-81 cit 72 (IgA1)	0.679	0.342	1.350	0.2696	0.5727
H2B/a 62-81 cit cyclic (IgA2)	0.227	0.015	3.327	0.2788	0.5727
H4 33-48 cit 39 (IgA1)	0.662	0.314	1.397	0.2790	0.5727
H2A/a 1-20 cit cyclic (IgA2)	1.770	0.615	5.093	0.2895	0.5789

Clusterin 221-240 cit cyclic (IgA1)	0.665	0.308	1.434	0.2979	0.5789
Clusterin 231-250 cit cyclic (IgA2)	0.784	0.489	1.257	0.3117	0.5789
FibrinogenA 27-43 cit (IgA2)	0.725	0.389	1.351	0.3117	0.5789
FibrinogenB 36-52 cit (IgA1)	0.628	0.244	1.614	0.3342	0.6062
Vimentin 1-16 cit (IgA2)	0.260	0.016	4.285	0.3460	0.6134
Vimentin 1-16 cit (IgA1)	0.711	0.333	1.518	0.3780	0.6531
Collagen Type II 281-298 cit 290 (IgG)	0.709	0.326	1.540	0.3852	0.6531
Clusterin 231-250 cit cyclic (IgA1)	0.852	0.579	1.253	0.4157	0.6899
FibrinogenA 563-583 cit 573 (IgA2)	0.716	0.301	1.704	0.4504	0.7319
Fibronectin cit 1035 1036 (IgG)	1.180	0.754	1.845	0.4696	0.7403
Fibronectin cit 1035 1036 (IgA2)	0.792	0.418	1.502	0.4752	0.7403
Enolase-1A 5-21 cit (IgG)	0.829	0.489	1.403	0.4841	0.7403
FibrinogenA 563-583 cit 573 (IgG)	0.808	0.389	1.677	0.5665	0.8474
B-actin 191-216 cit 196.206.210 (IgA1)	0.854	0.492	1.483	0.5758	0.8474
B-actin 191-216 cit 196.206.210 (IgA2)	0.744	0.248	2.227	0.5968	0.8616
B-actin 191-216 cit 196.206.210 (IgG)	0.859	0.476	1.551	0.6149	0.8616
Vimentin 1-16 cit (IgG)	0.836	0.405	1.726	0.6285	0.8616
Enolase-1A 5-21 cit (IgA2)	0.778	0.280	2.165	0.6310	0.8616
FibrinogenB 246-267 cit (IgG)	0.883	0.519	1.500	0.6446	0.8616
FibrinogenB 54-74 cit 60 72 74 (IgA2)	0.653	0.102	4.160	0.6517	0.8616
FibrinogenB 62-81 cit 72 (IgG)	0.879	0.477	1.620	0.6799	0.8740
Clusterin 221-240 cit cyclic (IgG)	1.131	0.626	2.041	0.6835	0.8740
FibrinogenA 41-60 cit3 cyclic (IgA2)	0.724	0.132	3.983	0.7106	0.8874
Biglycan 247-266 cit cyclic (IgG)	1.131	0.541	2.366	0.7428	0.8874
Vimentin 58-77 cit3 cyclic (IgA2)	0.898	0.467	1.724	0.7456	0.8874
FibrinogenA 27-43 cit (IgG)	0.932	0.606	1.434	0.7481	0.8874
H2A/a-2 1-20 cit (IgG)	0.888	0.420	1.875	0.7547	0.8874
FibrinogenB 36-52 cit (IgG)	0.912	0.504	1.652	0.7622	0.8874
Filaggrin 48-65 cit2 cyclic (IgA1)	0.829	0.214	3.208	0.7859	0.8972
H2A/a 1-20 cit cyclic (IgG)	0.916	0.474	1.770	0.7937	0.8972
FibrinogenB 62-81 cit 74 (IgG)	0.922	0.482	1.762	0.8058	0.8979
FibrinogenA 41-60 cit3 cyclic (IgA1)	0.921	0.447	1.898	0.8233	0.9044
H4 33-48 cit 39 40 (IgA1)	1.035	0.676	1.585	0.8747	0.9476
Clusterin 221-240 cit cyclic (IgA2)	0.937	0.294	2.980	0.9120	0.9476
FibrinogenA 616-635 cit3 cyclic (IgA2)	1.062	0.332	3.392	0.9194	0.9476
FibrinogenB 285-305 cit (IgG)	0.974	0.580	1.636	0.9211	0.9476
FibrinogenA 616-635 cit3 cyclic (IgG)	0.973	0.512	1.851	0.9336	0.9476
FibrinogenA 563-583 cit 573 (IgA1)	0.976	0.541	1.760	0.9355	0.9476
Vimentin 58-77 cit3 cyclic (IgG)	0.987	0.537	1.813	0.9654	0.9654

Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S9. All adjusted associations between autoantibodies to native proteins and incident UIP/fibrotic NSIP subtype of RA-ILD**

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
tenascin C 1 (IgA2)	<0.001	<0.001	0.321	0.0201	0.3402
FibrinogenB 54-74 (IgA2)	0.025	0.001	0.606	0.0232	0.3402
tenascin C 1 (IgG)	0.352	0.130	0.954	0.0400	0.3402
tenascin C 1 (IgA1)	0.279	0.082	0.946	0.0404	0.3402
FibrinogenB 62-81 (IgA2)	0.148	0.018	1.205	0.0742	0.3402
H2A/a 1-20 cyclic (IgA2)	3.407	0.866	13.403	0.0793	0.3402
Vimentin 265-278 (IgA2)	0.096	0.007	1.323	0.0800	0.3402
FibrinogenB 62-81 (IgA1)	0.479	0.207	1.109	0.0856	0.3402
Vimentin 58-77 cyclic (IgA1)	0.350	0.100	1.228	0.1013	0.3402
Vimentin 265-278 (IgG)	0.538	0.251	1.152	0.1106	0.3402
FibrinogenB 54-74 (IgG)	0.495	0.208	1.177	0.1117	0.3402
H2A/a-2 1-20 (IgA2)	3.227	0.757	13.766	0.1134	0.3402
Vimentin 265-278 (IgA1)	0.339	0.089	1.293	0.1134	0.3402
FibrinogenB 285-305 (IgG)	0.488	0.188	1.263	0.1393	0.3791
FibrinogenB 54-74 (IgA1)	0.485	0.182	1.294	0.1486	0.3791
Collagen Type II 281-298 (IgA2)	0.124	0.007	2.209	0.1555	0.3791
Vimentin 1-16 (IgA2)	0.159	0.011	2.395	0.1841	0.4186
tenascin C 5 (IgA1)	0.484	0.162	1.444	0.1932	0.4186
Collagen Type II 281-298 (IgA1)	0.560	0.224	1.403	0.2161	0.4306
H2B/a 62-81 cyclic (IgA1)	0.518	0.180	1.485	0.2208	0.4306
tenascin C 5 (IgG)	0.647	0.315	1.328	0.2351	0.4366
Vimentin 1-16 (IgA1)	0.594	0.243	1.456	0.2551	0.4522
H2B/a 62-81 cyclic (IgG)	0.721	0.386	1.348	0.3054	0.4868
H2B/a 62-81 cyclic (IgA2)	0.322	0.036	2.867	0.3097	0.4868
H2A/a-2 1-20 (IgA1)	0.721	0.382	1.360	0.3120	0.4868
Vimentin 1-16 (IgG)	0.720	0.350	1.479	0.3708	0.5563
Collagen Type II 281-298 (IgG)	0.751	0.370	1.525	0.4283	0.6187
Filaggrin 48-65 cyclic (IgA1)	0.607	0.158	2.328	0.4669	0.6399
Filaggrin 48-65 cyclic (IgG)	1.288	0.643	2.581	0.4758	0.6399
FibrinogenB 285-305 (IgA1)	1.249	0.536	2.911	0.6059	0.7877
H2A/a 1-20 cyclic (IgA1)	0.869	0.439	1.719	0.6863	0.8634
FibrinogenB 285-305 (IgA2)	1.502	0.133	16.918	0.7419	0.9042
FibrinogenB 62-81 (IgG)	0.913	0.495	1.685	0.7709	0.9111
tenascin C 5 (IgA2)	0.712	0.042	12.138	0.8142	0.9248
H2A/a 1-20 cyclic (IgG)	1.085	0.515	2.288	0.8299	0.9248
Vimentin 58-77 cyclic (IgA2)	0.824	0.056	12.145	0.8882	0.9622
Filaggrin 48-65 cyclic (IgA2)	1.071	0.097	11.864	0.9555	0.9845
H2A/a-2 1-20 (IgG)	0.983	0.445	2.171	0.9666	0.9845
Vimentin 58-77 cyclic (IgG)	1.007	0.504	2.013	0.9845	0.9845

Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S10.** All adjusted\* associations between autoantibodies to citrullinated proteins and incident RA-ILD among **seropositive RA**

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
H4 33-48 cit 39 (IgA2)	0.101	0.035	0.287	<.0001	0.0013
H2A/a-2 1-20 cit (IgA2)	3.573	1.765	7.232	0.0004	0.0157
Filaggrin 48-65 cit2 cyclic (IgG)	2.841	1.426	5.661	0.0030	0.0777
Clusterin 231-250 cit cyclic (IgG)	1.290	1.046	1.592	0.0173	0.3368
H4 33-48 cit 39 40 (IgG)	1.263	1.029	1.552	0.0259	0.3652
FibrinogenB 36-52 cit (IgA2)	0.386	0.164	0.911	0.0297	0.3652
Fibronectin cit 1035 1036 (IgG)	1.248	1.013	1.538	0.0371	0.3652
Biglycan 247-266 cit cyclic (IgA1)	0.699	0.499	0.979	0.0375	0.3652
Filaggrin 48-65 cit2 cyclic (IgA2)	4.806	0.983	23.491	0.0525	0.4547
FibrinogenB 285-305 cit (IgG)	1.392	0.978	1.981	0.0665	0.4798
FibrinogenB 62-81 cit 74 (IgA1)	0.781	0.599	1.018	0.0677	0.4798
Vimentin 58-77 cit3 cyclic (IgA1)	0.773	0.577	1.036	0.0847	0.5131
H2A/a 1-20 cit cyclic (IgA2)	1.530	0.932	2.512	0.0926	0.5131
H4 33-48 cit 39 (IgG)	1.272	0.948	1.709	0.1092	0.5131
Clusterin 221-240 cit cyclic (IgA1)	0.787	0.582	1.064	0.1190	0.5131
H2A/a-2 1-20 cit (IgA1)	0.780	0.570	1.068	0.1213	0.5131
H2B/a 62-81 cit cyclic (IgA1)	0.757	0.527	1.088	0.1329	0.5131
FibrinogenA 27-43 cit (IgA2)	0.721	0.468	1.111	0.1383	0.5131
FibrinogenB 54-74 cit 60 72 74 (IgA1)	0.770	0.541	1.095	0.1456	0.5131
Biglycan 247-266 cit cyclic (IgA2)	0.537	0.232	1.243	0.1464	0.5131
B-actin 191-216 cit 196.206.210 (IgG)	1.250	0.921	1.695	0.1522	0.5131
FibrinogenA 27-43 cit (IgA1)	0.815	0.614	1.081	0.1558	0.5131
Vimentin 1-16 cit (IgA1)	0.765	0.528	1.109	0.1578	0.5131
H2A/a 1-20 cit cyclic (IgA1)	0.824	0.629	1.078	0.1579	0.5131
FibrinogenB 62-81 cit 72 (IgA1)	0.822	0.620	1.090	0.1737	0.5419
FibrinogenA 41-60 cit3 cyclic (IgA2)	1.804	0.722	4.507	0.2069	0.6052
Collagen Type II 281-298 cit 290 (IgA1)	0.815	0.592	1.122	0.2095	0.6052
FibrinogenB 54-74 cit 60 72 74 (IgG)	1.251	0.871	1.797	0.2258	0.6230
FibrinogenA 616-635 cit3 cyclic (IgA1)	0.854	0.656	1.112	0.2409	0.6230
FibrinogenA 563-583 cit 573 (IgA2)	1.282	0.842	1.953	0.2474	0.6230
Enolase-1A 5-21 cit (IgA1)	0.865	0.677	1.106	0.2476	0.6230
Vimentin 58-77 cit3 cyclic (IgA2)	1.372	0.788	2.387	0.2633	0.6417
FibrinogenB 246-267 cit (IgG)	1.211	0.858	1.708	0.2754	0.6508
FibrinogenB 246-267 cit (IgA1)	0.809	0.543	1.204	0.2958	0.6786
H2B/a 62-81 cit cyclic (IgG)	0.849	0.611	1.180	0.3290	0.7331
FibrinogenB 285-305 cit (IgA1)	0.843	0.587	1.210	0.3540	0.7671
Filaggrin 48-65 cit2 cyclic (IgA1)	1.371	0.693	2.713	0.3652	0.7691
H4 33-48 cit 39 40 (IgA1)	1.092	0.897	1.329	0.3818	0.7691
Fibronectin cit 1035 1036 (IgA2)	1.132	0.855	1.498	0.3870	0.7691

Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S11.** All adjusted\* associations between autoantibodies to native proteins and incident RA-ILD among seropositive RA

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
H2A/a 1-20 cyclic (IgA2)	5.066	2.163	11.866	0.0002	0.0036
H2A/a-2 1-20 (IgA2)	4.357	2.021	9.392	0.0002	0.0036
Filaggrin 48-65 cyclic (IgG)	2.191	1.260	3.810	0.0055	0.0709
H2A/a 1-20 cyclic (IgG)	1.858	1.128	3.058	0.0149	0.1444
tenascin C 1 (IgA1)	0.692	0.507	0.944	0.0201	0.1444
H2A/a-2 1-20 (IgG)	1.804	1.088	2.990	0.0222	0.1444
tenascin C 1 (IgG)	0.711	0.509	0.993	0.0454	0.2532
Vimentin 58-77 cyclic (IgG)	1.474	0.978	2.221	0.0636	0.3098
tenascin C 1 (IgA2)	0.497	0.214	1.153	0.1034	0.4480
tenascin C 5 (IgA1)	0.748	0.509	1.098	0.1385	0.5032
Vimentin 58-77 cyclic (IgA2)	1.764	0.827	3.763	0.1419	0.5032
FibrinogenB 62-81 (IgA1)	0.812	0.601	1.097	0.1749	0.5685
H2A/a-2 1-20 (IgA1)	1.243	0.891	1.734	0.2006	0.5815
H2A/a 1-20 cyclic (IgA1)	1.244	0.885	1.747	0.2087	0.5815
FibrinogenB 285-305 (IgA1)	0.812	0.555	1.186	0.2806	0.7296
FibrinogenB 54-74 (IgA1)	0.851	0.620	1.168	0.3174	0.7736
FibrinogenB 285-305 (IgG)	0.829	0.554	1.239	0.3598	0.8253
Collagen Type II 281-298 (IgA1)	0.877	0.625	1.231	0.4487	0.8906
Filaggrin 48-65 cyclic (IgA2)	0.639	0.172	2.381	0.5049	0.8906
Vimentin 1-16 (IgA1)	0.900	0.638	1.268	0.5461	0.8906
tenascin C 5 (IgG)	0.893	0.615	1.296	0.5515	0.8906
Vimentin 265-278 (IgA1)	0.906	0.638	1.286	0.5797	0.8906
H2B/a 62-81 cyclic (IgA1)	0.908	0.636	1.295	0.5935	0.8906
Filaggrin 48-65 cyclic (IgA1)	1.180	0.641	2.169	0.5950	0.8906
FibrinogenB 54-74 (IgG)	0.901	0.607	1.339	0.6068	0.8906
Vimentin 265-278 (IgG)	0.904	0.615	1.329	0.6083	0.8906
FibrinogenB 54-74 (IgA2)	0.868	0.491	1.533	0.6248	0.8906
Vimentin 58-77 cyclic (IgA1)	1.081	0.764	1.529	0.6615	0.8906
H2B/a 62-81 cyclic (IgA2)	1.145	0.624	2.101	0.6623	0.8906
FibrinogenB 62-81 (IgA2)	0.884	0.481	1.626	0.6924	0.9001
FibrinogenB 62-81 (IgG)	1.059	0.748	1.500	0.7458	0.9166
FibrinogenB 285-305 (IgA2)	1.124	0.544	2.321	0.7521	0.9166
Vimentin 1-16 (IgA2)	0.909	0.439	1.881	0.7960	0.9395
Vimentin 1-16 (IgG)	1.050	0.693	1.591	0.8191	0.9395
H2B/a 62-81 cyclic (IgG)	0.972	0.672	1.405	0.8791	0.9636
Collagen Type II 281-298 (IgG)	0.973	0.659	1.435	0.8895	0.9636
tenascin C 5 (IgA2)	1.035	0.398	2.694	0.9437	0.9890
Collagen Type II 281-298 (IgA2)	0.995	0.518	1.911	0.9881	0.9890
Vimentin 265-278 (IgA2)	1.005	0.503	2.006	0.9890	0.9890

**Table S12.** All adjusted\* associations between autoantibodies to citrullinated proteins and incident RA-ILD among seronegative RA

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
H2A/a 1-20 cyclic (IgA2)	5.066	2.163	11.866	0.0002	0.0036
H2A/a-2 1-20 (IgA2)	4.357	2.021	9.392	0.0002	0.0036
Filaggrin 48-65 cyclic (IgG)	2.191	1.260	3.810	0.0055	0.0709
H2A/a 1-20 cyclic (IgG)	1.858	1.128	3.058	0.0149	0.1444
tenascin C 1 (IgA1)	0.692	0.507	0.944	0.0201	0.1444
H2A/a-2 1-20 (IgG)	1.804	1.088	2.990	0.0222	0.1444
tenascin C 1 (IgG)	0.711	0.509	0.993	0.0454	0.2532
Vimentin 58-77 cyclic (IgG)	1.474	0.978	2.221	0.0636	0.3098
tenascin C 1 (IgA2)	0.497	0.214	1.153	0.1034	0.4480
tenascin C 5 (IgA1)	0.748	0.509	1.098	0.1385	0.5032
Vimentin 58-77 cyclic (IgA2)	1.764	0.827	3.763	0.1419	0.5032
FibrinogenB 62-81 (IgA1)	0.812	0.601	1.097	0.1749	0.5685
H2A/a-2 1-20 (IgA1)	1.243	0.891	1.734	0.2006	0.5815
H2A/a 1-20 cyclic (IgA1)	1.244	0.885	1.747	0.2087	0.5815
FibrinogenB 285-305 (IgA1)	0.812	0.555	1.186	0.2806	0.7296
FibrinogenB 54-74 (IgA1)	0.851	0.620	1.168	0.3174	0.7736
FibrinogenB 285-305 (IgG)	0.829	0.554	1.239	0.3598	0.8253
Collagen Type II 281-298 (IgA1)	0.877	0.625	1.231	0.4487	0.8906
Filaggrin 48-65 cyclic (IgA2)	0.639	0.172	2.381	0.5049	0.8906
Vimentin 1-16 (IgA1)	0.900	0.638	1.268	0.5461	0.8906
tenascin C 5 (IgG)	0.893	0.615	1.296	0.5515	0.8906
Vimentin 265-278 (IgA1)	0.906	0.638	1.286	0.5797	0.8906
H2B/a 62-81 cyclic (IgA1)	0.908	0.636	1.295	0.5935	0.8906
Filaggrin 48-65 cyclic (IgA1)	1.180	0.641	2.169	0.5950	0.8906
FibrinogenB 54-74 (IgG)	0.901	0.607	1.339	0.6068	0.8906
Vimentin 265-278 (IgG)	0.904	0.615	1.329	0.6083	0.8906
FibrinogenB 54-74 (IgA2)	0.868	0.491	1.533	0.6248	0.8906
Vimentin 58-77 cyclic (IgA1)	1.081	0.764	1.529	0.6615	0.8906
H2B/a 62-81 cyclic (IgA2)	1.145	0.624	2.101	0.6623	0.8906
FibrinogenB 62-81 (IgA2)	0.884	0.481	1.626	0.6924	0.9001
FibrinogenB 62-81 (IgG)	1.059	0.748	1.500	0.7458	0.9166
FibrinogenB 285-305 (IgA2)	1.124	0.544	2.321	0.7521	0.9166
Vimentin 1-16 (IgA2)	0.909	0.439	1.881	0.7960	0.9395
Vimentin 1-16 (IgG)	1.050	0.693	1.591	0.8191	0.9395
H2B/a 62-81 cyclic (IgG)	0.972	0.672	1.405	0.8791	0.9636
Collagen Type II 281-298 (IgG)	0.973	0.659	1.435	0.8895	0.9636
tenascin C 5 (IgA2)	1.035	0.398	2.694	0.9437	0.9890
Collagen Type II 281-298 (IgA2)	0.995	0.518	1.911	0.9881	0.9890
Vimentin 265-278 (IgA2)	1.005	0.503	2.006	0.9890	0.9890

Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S13.** All adjusted\* associations between autoantibodies to native proteins and incident RA-ILD among seronegative RA

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
tenascin C 5 (IgG)	0.128	0.020	0.801	0.0280	0.5611
tenascin C 1 (IgG)	0.120	0.017	0.835	0.0322	0.5611
H2B/a 62-81 cyclic (IgG)	0.023	<0.001	0.936	0.0461	0.5611
Collagen Type II 281-298 (IgG)	0.148	0.020	1.079	0.0595	0.5611
H2A/a 1-20 cyclic (IgA2)	>999.999	0.483	>999.999	0.0755	0.5611
Filaggrin 48-65 cyclic (IgG)	64.275	0.500	>999.999	0.0929	0.5611
H2A/a-2 1-20 (IgA2)	43.200	0.481	>999.999	0.1007	0.5611
Filaggrin 48-65 cyclic (IgA1)	3.638	0.691	19.154	0.1276	0.6024
Vimentin 58-77 cyclic (IgA1)	1.886	0.807	4.408	0.1429	0.6024
Vimentin 265-278 (IgG)	0.398	0.108	1.465	0.1657	0.6024
H2A/a 1-20 cyclic (IgG)	3.738	0.539	25.899	0.1819	0.6024
FibrinogenB 54-74 (IgG)	0.380	0.086	1.685	0.2030	0.6024
tenascin C 1 (IgA1)	2.865	0.547	15.003	0.2128	0.6024
FibrinogenB 62-81 (IgA2)	0.183	0.012	2.771	0.2204	0.6024
H2A/a-2 1-20 (IgG)	3.456	0.423	28.223	0.2471	0.6024
tenascin C 5 (IgA2)	0.156	0.007	3.630	0.2472	0.6024
Vimentin 1-16 (IgG)	0.493	0.113	2.161	0.3483	0.7837
Filaggrin 48-65 cyclic (IgA2)	10.350	0.055	>999.999	0.3813	0.7837
H2B/a 62-81 cyclic (IgA2)	0.421	0.048	3.730	0.4372	0.7837
Vimentin 265-278 (IgA2)	0.361	0.024	5.484	0.4628	0.7837
Vimentin 58-77 cyclic (IgG)	1.777	0.382	8.269	0.4637	0.7837
Vimentin 1-16 (IgA2)	0.334	0.018	6.334	0.4652	0.7837
tenascin C 5 (IgA1)	1.634	0.413	6.463	0.4842	0.7837
Collagen Type II 281-298 (IgA2)	0.416	0.035	4.959	0.4880	0.7837
FibrinogenB 285-305 (IgA2)	0.401	0.024	6.704	0.5248	0.7837
FibrinogenB 285-305 (IgG)	0.684	0.199	2.356	0.5475	0.7837
FibrinogenB 62-81 (IgG)	0.699	0.209	2.340	0.5613	0.7837
FibrinogenB 285-305 (IgA1)	1.353	0.484	3.782	0.5646	0.7837
FibrinogenB 54-74 (IgA1)	1.297	0.489	3.438	0.6012	0.7837
Vimentin 58-77 cyclic (IgA2)	1.970	0.153	25.362	0.6029	0.7837
H2A/a-2 1-20 (IgA1)	0.742	0.207	2.666	0.6475	0.8146
FibrinogenB 54-74 (IgA2)	0.648	0.081	5.207	0.6829	0.8219
Vimentin 1-16 (IgA1)	1.208	0.468	3.118	0.6955	0.8219
H2A/a 1-20 cyclic (IgA1)	0.799	0.234	2.728	0.7203	0.8262
Vimentin 265-278 (IgA1)	1.132	0.428	2.994	0.8029	0.8792
Collagen Type II 281-298 (IgA1)	1.122	0.437	2.882	0.8116	0.8792
FibrinogenB 62-81 (IgA1)	0.952	0.370	2.450	0.9185	0.9681
tenascin C 1 (IgA2)	1.163	0.011	120.371	0.9493	0.9742
H2B/a 62-81 cyclic (IgA1)	1.008	0.410	2.477	0.9862	0.9862

Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S14.** All adjusted\* associations between autoantibodies to citrullinated proteins and incident RA-ILD among **anti-CCP-positive RA**

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
H4 33-48 cit 39 (IgA2)	0.132	0.047	0.375	0.0001	0.0110
H2A/a-2 1-20 cit (IgA2)	3.556	1.655	7.644	0.0012	0.0451
Filaggrin 48-65 cit2 cyclic (IgG)	2.625	1.347	5.114	0.0046	0.1190
FibrinogenB 36-52 cit (IgA2)	0.308	0.123	0.774	0.0122	0.2382
Biglycan 247-266 cit cyclic (IgA1)	0.683	0.476	0.981	0.0390	0.5017
H4 33-48 cit 39 40 (IgG)	1.249	1.005	1.553	0.0450	0.5017
FibrinogenB 62-81 cit 74 (IgA1)	0.752	0.567	0.996	0.0471	0.5017
Fibronectin cit 1035 1036 (IgG)	1.233	0.996	1.526	0.0543	0.5017
H2A/a 1-20 cit cyclic (IgA2)	1.654	0.951	2.875	0.0746	0.5017
Vimentin 58-77 cit3 cyclic (IgA1)	0.755	0.548	1.040	0.0851	0.5017
Filaggrin 48-65 cit2 cyclic (IgA2)	4.030	0.808	20.114	0.0892	0.5017
FibrinogenB 54-74 cit 60 72 74 (IgA1)	0.718	0.489	1.055	0.0919	0.5017
Clusterin 231-250 cit cyclic (IgG)	1.210	0.969	1.512	0.0930	0.5017
FibrinogenB 285-305 cit (IgG)	1.376	0.943	2.008	0.0981	0.5017
H4 33-48 cit 39 (IgG)	1.296	0.949	1.768	0.1026	0.5017
Enolase-1A 5-21 cit (IgA1)	0.802	0.614	1.047	0.1047	0.5017
H2B/a 62-81 cit cyclic (IgA1)	0.732	0.494	1.084	0.1194	0.5017
FibrinogenB 62-81 cit 72 (IgA1)	0.789	0.585	1.064	0.1207	0.5017
FibrinogenA 27-43 cit (IgA1)	0.792	0.589	1.064	0.1222	0.5017
H2A/a-2 1-20 cit (IgA1)	0.778	0.561	1.080	0.1333	0.5037
Clusterin 221-240 cit cyclic (IgA1)	0.781	0.564	1.081	0.1356	0.5037
Vimentin 1-16 cit (IgA1)	0.746	0.504	1.104	0.1427	0.5059
H2B/a 62-81 cit cyclic (IgG)	0.783	0.554	1.108	0.1675	0.5240
Collagen Type II 281-298 cit 290 (IgA1)	0.790	0.566	1.104	0.1676	0.5240
H2A/a 1-20 cit cyclic (IgA1)	0.820	0.619	1.087	0.1680	0.5240
Biglycan 247-266 cit cyclic (IgA2)	0.573	0.250	1.317	0.1896	0.5688
FibrinogenA 27-43 cit (IgA2)	0.759	0.498	1.157	0.1994	0.5760
FibrinogenA 616-635 cit3 cyclic (IgA1)	0.830	0.622	1.109	0.2074	0.5778
H2B/a 62-81 cit cyclic (IgA2)	0.381	0.071	2.045	0.2602	0.6999
FibrinogenA 41-60 cit3 cyclic (IgA2)	1.694	0.663	4.327	0.2707	0.7000
FibrinogenB 62-81 cit 74 (IgG)	0.831	0.596	1.161	0.2782	0.7000
Vimentin 58-77 cit3 cyclic (IgA2)	1.337	0.778	2.299	0.2932	0.7035
FibrinogenB 246-267 cit (IgA1)	0.800	0.523	1.224	0.3038	0.7035
Clusterin 231-250 cit cyclic (IgA1)	0.892	0.716	1.111	0.3067	0.7035
FibrinogenB 285-305 cit (IgA1)	0.824	0.562	1.208	0.3214	0.7162
B-actin 191-216 cit 196.206.210 (IgG)	1.160	0.848	1.586	0.3536	0.7662
FibrinogenB 246-267 cit (IgG)	1.180	0.820	1.697	0.3737	0.7877
FibrinogenA 563-583 cit 573 (IgA2)	1.212	0.763	1.926	0.4157	0.8254
Fibronectin cit 1035 1036 (IgA2)	1.122	0.848	1.483	0.4202	0.8254

Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S15.** All adjusted\* associations between autoantibodies to native proteins and incident RA-ILD among anti-CCP-positive RA

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
H2A/a 1-20 cyclic (IgA2)	4.321	1.857	10.052	0.0007	0.0133
H2A/a-2 1-20 (IgA2)	3.918	1.785	8.599	0.0007	0.0133
Filaggrin 48-65 cyclic (IgG)	2.065	1.171	3.639	0.0122	0.1584
tenascin C 1 (IgA1)	0.691	0.503	0.950	0.0230	0.2245
H2A/a 1-20 cyclic (IgG)	1.750	1.051	2.913	0.0314	0.2449
H2A/a-2 1-20 (IgG)	1.670	0.994	2.806	0.0529	0.3040
tenascin C 1 (IgG)	0.709	0.499	1.007	0.0546	0.3040
FibrinogenB 285-305 (IgA1)	0.702	0.462	1.066	0.0967	0.4325
tenascin C 1 (IgA2)	0.497	0.215	1.151	0.1028	0.4325
tenascin C 5 (IgA1)	0.719	0.475	1.087	0.1178	0.4325
FibrinogenB 62-81 (IgA1)	0.779	0.568	1.069	0.1220	0.4325
Vimentin 58-77 cyclic (IgG)	1.373	0.900	2.095	0.1414	0.4595
H2A/a 1-20 cyclic (IgA1)	1.211	0.854	1.718	0.2820	0.7793
H2A/a-2 1-20 (IgA1)	1.204	0.857	1.691	0.2846	0.7793
FibrinogenB 285-305 (IgG)	0.799	0.518	1.231	0.3093	0.7793
FibrinogenB 54-74 (IgA1)	0.847	0.610	1.175	0.3199	0.7793
Vimentin 265-278 (IgA1)	0.836	0.575	1.215	0.3467	0.7793
tenascin C 5 (IgG)	0.830	0.557	1.238	0.3618	0.7793
Filaggrin 48-65 cyclic (IgA2)	0.565	0.146	2.185	0.4078	0.7793
Collagen Type II 281-298 (IgA1)	0.869	0.610	1.236	0.4333	0.7793
Vimentin 1-16 (IgA1)	0.871	0.612	1.240	0.4446	0.7793
Vimentin 58-77 cyclic (IgA2)	1.365	0.610	3.054	0.4492	0.7793
FibrinogenB 54-74 (IgG)	0.856	0.567	1.293	0.4596	0.7793
H2B/a 62-81 cyclic (IgA1)	0.881	0.611	1.271	0.4994	0.8115
Vimentin 265-278 (IgG)	0.886	0.591	1.329	0.5590	0.8686
FibrinogenB 54-74 (IgA2)	0.851	0.475	1.523	0.5862	0.8686
FibrinogenB 62-81 (IgA2)	0.849	0.447	1.613	0.6167	0.8686
Vimentin 1-16 (IgA2)	0.829	0.392	1.752	0.6236	0.8686
Vimentin 265-278 (IgA2)	0.888	0.431	1.830	0.7483	0.9732
H2B/a 62-81 cyclic (IgG)	0.944	0.648	1.377	0.7653	0.9732
H2B/a 62-81 cyclic (IgA2)	1.094	0.592	2.024	0.7736	0.9732
Collagen Type II 281-298 (IgG)	0.963	0.645	1.438	0.8533	0.9906
Collagen Type II 281-298 (IgA2)	0.944	0.487	1.829	0.8649	0.9906
FibrinogenB 62-81 (IgG)	1.030	0.714	1.485	0.8752	0.9906
FibrinogenB 285-305 (IgA2)	0.959	0.441	2.084	0.9160	0.9906
tenascin C 5 (IgA2)	0.977	0.370	2.578	0.9621	0.9906
Filaggrin 48-65 cyclic (IgA1)	0.990	0.519	1.888	0.9764	0.9906
Vimentin 58-77 cyclic (IgA1)	1.003	0.695	1.446	0.9885	0.9906
Vimentin 1-16 (IgG)	0.997	0.655	1.518	0.9906	0.9906

Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S16.** All adjusted\* associations between autoantibodies to citrullinated proteins and incident RA-ILD among **anti-CCP-negative RA**

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
H4 33-48 cit 39 (IgA2)	<0.001	<0.001	0.063	0.0023	0.1775
H2A/a-2 1-20 cit (IgA2)	283.081	5.108	>999.999	0.0059	0.1856
H4 33-48 cit 39 40 (IgA2)	<0.001	<0.001	0.115	0.0071	0.1856
Filaggrin 48-65 cit2 cyclic (IgG)	>999.999	6.601	>999.999	0.0152	0.2483
FibrinogenA 616-635 cit3 cyclic (IgG)	0.148	0.031	0.705	0.0165	0.2483
Filaggrin 48-65 cit2 cyclic (IgA1)	>999.999	3.939	>999.999	0.0209	0.2483
Clusterin 231-250 cit cyclic (IgA1)	3.862	1.211	12.320	0.0224	0.2483
H2A/a 1-20 cit cyclic (IgA2)	19.233	1.393	265.577	0.0273	0.2483
Vimentin 58-77 cit3 cyclic (IgA2)	143.770	1.679	>999.999	0.0286	0.2483
FibrinogenA 27-43 cit (IgA2)	74.794	1.448	>999.999	0.0321	0.2500
Fibronectin cit 1035 1036 (IgG)	0.270	0.069	1.056	0.0599	0.4116
FibrinogenA 27-43 cit (IgA1)	3.734	0.880	15.855	0.0741	0.4116
Collagen Type II 281-298 cit 290 (IgG)	0.373	0.125	1.109	0.0760	0.4116
FibrinogenA 211-230 cit cyclic (IgA1)	3.031	0.888	10.342	0.0767	0.4116
Clusterin 221-240 cit cyclic (IgG)	0.383	0.131	1.118	0.0792	0.4116
Vimentin 58-77 cit3 cyclic (IgG)	0.392	0.130	1.184	0.0970	0.4250
Enolase-1A 5-21 cit (IgA1)	3.212	0.793	13.019	0.1022	0.4250
Filaggrin 48-65 cit2 cyclic (IgA2)	79.199	0.415	>999.999	0.1028	0.4250
Vimentin 1-16 cit (IgG)	0.405	0.134	1.220	0.1082	0.4250
H2B/a 62-81 cit cyclic (IgG)	0.421	0.146	1.213	0.1090	0.4250
Biglycan 247-266 cit cyclic (IgA1)	2.570	0.795	8.312	0.1150	0.4271
FibrinogenB 285-305 cit (IgA2)	0.244	0.040	1.478	0.1248	0.4305
FibrinogenA 41-60 cit3 cyclic (IgA1)	1.968	0.825	4.693	0.1270	0.4305
FibrinogenB 54-74 cit 60 72 74 (IgA1)	2.139	0.752	6.083	0.1539	0.5002
Vimentin 1-16 cit (IgA1)	2.603	0.619	10.949	0.1918	0.5928
FibrinogenB 36-52 cit (IgA1)	1.744	0.748	4.066	0.1977	0.5928
Clusterin 231-250 cit cyclic (IgA2)	4.853	0.421	55.880	0.2052	0.5928
FibrinogenA 211-230 cit cyclic (IgG)	0.480	0.149	1.549	0.2196	0.6118
FibrinogenA 563-583 cit 573 (IgA1)	1.569	0.739	3.332	0.2410	0.6483
H4 33-48 cit 39 (IgA1)	1.728	0.671	4.448	0.2569	0.6655
Biglycan 247-266 cit cyclic (IgG)	0.506	0.153	1.675	0.2645	0.6655
H2A/a 1-20 cit cyclic (IgA1)	1.738	0.613	4.931	0.2988	0.7145
Clusterin 221-240 cit cyclic (IgA1)	1.749	0.588	5.199	0.3148	0.7145
FibrinogenB 36-52 cit (IgG)	0.531	0.152	1.855	0.3214	0.7145
Vimentin 58-77 cit3 cyclic (IgA1)	1.756	0.557	5.533	0.3362	0.7145
FibrinogenB 246-267 cit (IgA2)	0.365	0.047	2.868	0.3381	0.7145
H4 33-48 cit 39 (IgG)	1.694	0.575	4.990	0.3389	0.7145
FibrinogenB 54-74 cit 60 72 74 (IgA2)	3.126	0.272	35.959	0.3604	0.7280
Biglycan 247-266 cit cyclic (IgA2)	4.424	0.175	111.857	0.3669	0.7280

Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S17.** All adjusted\* associations between autoantibodies to native proteins and incident RA-ILD among anti-CCP-negative RA

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
Filaggrin 48-65 cyclic (IgG)	107.801	2.307	>999.999	0.0170	0.2989
H2A/a 1-20 cyclic (IgA2)	127.142	2.088	>999.999	0.0208	0.2989
H2A/a-2 1-20 (IgA2)	35.509	1.636	770.571	0.0230	0.2989
tenascin C 1 (IgG)	0.297	0.098	0.904	0.0325	0.3010
Vimentin 58-77 cyclic (IgA1)	2.265	1.016	5.048	0.0456	0.3010
Filaggrin 48-65 cyclic (IgA1)	4.221	1.024	17.403	0.0463	0.3010
H2B/a 62-81 cyclic (IgG)	0.352	0.117	1.061	0.0636	0.3542
tenascin C 5 (IgG)	0.418	0.155	1.128	0.0851	0.4146
Collagen Type II 281-298 (IgG)	0.359	0.108	1.201	0.0963	0.4174
Vimentin 58-77 cyclic (IgA2)	5.509	0.614	49.442	0.1275	0.4939
H2A/a 1-20 cyclic (IgG)	3.795	0.636	22.653	0.1435	0.4939
Vimentin 58-77 cyclic (IgG)	2.584	0.705	9.466	0.1520	0.4939
H2A/a-2 1-20 (IgG)	3.642	0.574	23.108	0.1704	0.5112
tenascin C 5 (IgA2)	0.103	0.002	4.813	0.2468	0.6875
tenascin C 1 (IgA2)	0.194	0.006	6.364	0.3574	0.8279
Vimentin 1-16 (IgA2)	0.268	0.014	5.145	0.3822	0.8279
Vimentin 265-278 (IgG)	0.648	0.226	1.858	0.4191	0.8279
FibrinogenB 62-81 (IgA2)	0.457	0.067	3.107	0.4233	0.8279
FibrinogenB 54-74 (IgA1)	1.439	0.578	3.582	0.4336	0.8279
FibrinogenB 285-305 (IgA1)	1.408	0.577	3.440	0.4523	0.8279
FibrinogenB 285-305 (IgA2)	0.349	0.020	5.995	0.4683	0.8279
Vimentin 265-278 (IgA1)	1.342	0.575	3.129	0.4962	0.8279
Collagen Type II 281-298 (IgA2)	0.483	0.047	4.991	0.5417	0.8279
H2B/a 62-81 cyclic (IgA2)	0.534	0.057	5.034	0.5840	0.8279
Filaggrin 48-65 cyclic (IgA2)	3.126	0.043	228.682	0.6028	0.8279
FibrinogenB 54-74 (IgA2)	0.572	0.068	4.803	0.6065	0.8279
Collagen Type II 281-298 (IgA1)	1.235	0.519	2.939	0.6339	0.8279
FibrinogenB 285-305 (IgG)	0.799	0.290	2.197	0.6634	0.8279
FibrinogenB 62-81 (IgA1)	1.179	0.557	2.496	0.6667	0.8279
H2B/a 62-81 cyclic (IgA1)	1.183	0.527	2.654	0.6836	0.8279
Vimentin 265-278 (IgA2)	0.625	0.063	6.173	0.6874	0.8279
FibrinogenB 54-74 (IgG)	0.797	0.253	2.507	0.6975	0.8279
Vimentin 1-16 (IgA1)	1.189	0.492	2.871	0.7006	0.8279
Vimentin 1-16 (IgG)	0.797	0.223	2.841	0.7260	0.8328
H2A/a-2 1-20 (IgA1)	0.867	0.293	2.566	0.7971	0.8881
H2A/a 1-20 cyclic (IgA1)	1.127	0.372	3.415	0.8319	0.9013
tenascin C 1 (IgA1)	0.944	0.351	2.537	0.9085	0.9576
tenascin C 5 (IgA1)	1.022	0.363	2.873	0.9678	0.9869
FibrinogenB 62-81 (IgG)	1.009	0.365	2.786	0.9869	0.9869

Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.

**Table S18.** All adjusted\* associations between autoantibodies after subtraction of results of native from citrullinated proteins and incident RA-ILD

Targeted antigen	OR	Lower 95% CL	Upper 95% CL	p-value	FDR-p
H4 33-48 cit 39 (IgA2)	0.078	0.028	0.219	<0.0001	0.0001
Filaggrin 48-65 cit2 cyclic (IgA2)	2.011	1.359	2.978	0.0005	0.0187
FibrinogenB 285-305 cit (IgG)	1.302	1.070	1.585	0.0085	0.2217
Filaggrin 48-65 cit2 cyclic (IgA1)	1.257	1.051	1.503	0.0121	0.2292
H2A/a-2 1-20 cit (IgA1)	0.775	0.632	0.951	0.0147	0.2292
FibrinogenB 36-52 cit (IgA2)	0.371	0.161	0.857	0.0203	0.2315
Filaggrin 48-65 cit2 cyclic (IgG)	1.180	1.026	1.358	0.0208	0.2315
Clusterin 231-250 cit cyclic (IgG)	1.266	1.029	1.558	0.0258	0.2519
H4 33-48 cit 39 40 (IgG)	1.251	1.021	1.533	0.0306	0.2649
Fibronectin cit 1035 1036 (IgG)	1.219	0.993	1.497	0.0584	0.4414
FibrinogenB 62-81 cit 74 (IgA1)	0.797	0.619	1.027	0.0792	0.4414
H4 33-48 cit 39 (IgG)	1.293	0.968	1.728	0.0818	0.4414
H2A/a 1-20 cit cyclic (IgG)	0.905	0.809	1.013	0.0833	0.4414
H2A/a 1-20 cit cyclic (IgA1)	0.880	0.762	1.017	0.0838	0.4414
H2B/a 62-81 cit cyclic (IgG)	0.857	0.719	1.021	0.0849	0.4414
Biglycan 247-266 cit cyclic (IgA1)	0.798	0.584	1.090	0.1556	0.6527
H2A/a 1-20 cit cyclic (IgA2)	0.798	0.580	1.097	0.1640	0.6527
FibrinogenA 41-60 cit3 cyclic (IgA2)	1.836	0.767	4.393	0.1723	0.6527
Collagen Type II 281-298 cit 290 (IgA1)	0.835	0.644	1.083	0.1746	0.6527
FibrinogenB 62-81 cit 72 (IgA1)	0.831	0.636	1.086	0.1758	0.6527
H2A/a-2 1-20 cit (IgA2)	0.806	0.588	1.105	0.1805	0.6527
Vimentin 1-16 cit (IgG)	0.883	0.734	1.063	0.1889	0.6527
FibrinogenB 285-305 cit (IgA2)	0.754	0.493	1.153	0.1925	0.6527
FibrinogenA 27-43 cit (IgA2)	0.765	0.501	1.167	0.2137	0.6946
Biglycan 247-266 cit cyclic (IgA2)	0.626	0.282	1.386	0.2477	0.7107
B-actin 191-216 cit 196.206.210 (IgG)	1.181	0.878	1.589	0.2706	0.7107
FibrinogenB 54-74 cit 60 72 74 (IgA1)	0.834	0.602	1.156	0.2761	0.7107
Clusterin 221-240 cit cyclic (IgA1)	0.852	0.638	1.139	0.2808	0.7107
FibrinogenA 616-635 cit3 cyclic (IgA1)	0.868	0.671	1.123	0.2819	0.7107
FibrinogenA 563-583 cit 573 (IgA2)	1.255	0.828	1.902	0.2853	0.7107
Collagen Type II 281-298 cit 290 (IgG)	0.915	0.776	1.079	0.2901	0.7107
Enolase-1A 5-21 cit (IgA2)	1.269	0.815	1.975	0.2916	0.7107
Fibronectin cit 1035 1036 (IgA2)	1.152	0.871	1.522	0.3219	0.7510
H2B/a 62-81 cit cyclic (IgA1)	0.891	0.706	1.124	0.3306	0.7510
FibrinogenA 27-43 cit (IgA1)	0.877	0.672	1.146	0.3370	0.7510
FibrinogenB 54-74 cit 60 72 74 (IgG)	1.180	0.829	1.679	0.3577	0.7728
FibrinogenB 246-267 cit (IgG)	1.162	0.838	1.612	0.3666	0.7728
H4 33-48 cit 39 40 (IgA1)	1.090	0.896	1.325	0.3879	0.7800
Enolase-1A 5-21 cit (IgA1)	0.900	0.707	1.145	0.3920	0.7800


Per log-transformed unit.

BMI = body mass index, CL = confidence limit, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, DMARD = disease-modifying anti-rheumatic drug, FDR = false discovery rate, H = histone, Ig = immunoglobulin, ILD = interstitial lung disease, MDHAQ = multi-dimensional health assessment questionnaire, OR = odds ratio, RA = rheumatoid arthritis, RF = rheumatoid factor

\*Adjusting for matching factors and covariates of BMI, smoking pack-years, DAS28-CRP, MDHAQ, rheumatoid nodules, bDMARD use, methotrexate use, glucocorticoid use, and MUC5B genotype.


**Figure S1.** Receiver operating characteristic curves for incident RA-ILD risk among 84 cases and 233 RA-nILD controls in BRASS for 6 novel biomarkers

ROC = receiver operating characteristic, Novel biomarkers = H4 33-48 cit 39 (IgA2), H2A/a-2 1-20 cit (IgA2), Filaggrin 48-65 cit2 cyclic (IgG), H2A/a 1-20 cyclic (IgA2), H2A/a-2 1-20 (IgA2), Filaggrin 48-65 cyclic (IgG)



**Figure S2.** Receiver operating characteristic curves for incident RA-ILD risk among 84 cases and 233 RA-noILD controls in BRASS for novel biomarkers grouped as autoantibodies to citrullinated or native proteins

ROC = receiver operating characteristic, Novel autoantibodies to citrullinated protein biomarkers: H4 33-48 cit 39 (IgA2), H2A/a-2 1-20 cit (IgA2), Filaggrin 48-65 cit2 cyclic (IgG). Novel autoantibodies to native protein biomarkers: H2A/a 1-20 cyclic (IgA2), H2A/a-2 1-20 (IgA2), Filaggrin 48-65 cyclic (IgG)



**Table S19.** Pairwise comparisons of AUCs between different models for incident RA-ILD risk

Models being compared	p-value
Demographics - MUC5B	0.6779
Demographics - Lifestyle	0.053
Demographics - RA factors	0.0006
Demographics - Demo, life and RA factors combined	<0.0001
Demographics - 6 biomarkers	<0.0001
Demographics - All combined	<0.0001
MUC5B - Lifestyle	0.0783
MUC5B - RA factors	0.0016
MUC5B - Demo, life and RA factors combined	<0.0001
MUC5B - 6 biomarkers	<0.0001
MUC5B - All combined	<0.0001
Lifestyle - RA factors	0.1344
Lifestyle - Demo, life and RA factors combined	0.0004
Lifestyle - 6 biomarkers	<0.0001
Lifestyle - All combined	<0.0001
RA factors - Demo, life and RA factors combined	0.0248
RA factors - 6 biomarkers	0.0043
RA factors - All combined	<0.0001
Demo, life and RA factors combined - 6 biomarkers	0.0735
Demo, life and RA factors combined - All combined	0.0002
6 biomarkers - All combined	0.0215

**Table S20. Model coefficients and odds ratios used for RA-ILD risk score development**

Risk score	Coefficient	OR	95% LCL	95% UCL
<i>Without biomarkers</i>				
Smoking pack-years ≥30	1.92	6.83	2.99	15.60
DAS28-CRP ≥3.2	1.17	3.21	1.65	6.23
Current glucocorticoid use	0.96	2.62	1.39	4.92
BMI ≥30 kg/m <sup>2</sup>	0.41	1.51	0.78	2.92
<i>With biomarkers</i>				
Smoking pack-years ≥30	2.29	9.90	2.48	39.51
DAS28-CRP ≥3.2	1.23	3.41	1.33	8.75
Current glucocorticoid use	1.24	3.46	1.27	9.41
BMI ≥30 kg/m <sup>2</sup>	0.76	2.13	0.78	5.81
Filaggrin 48-65 cit 2 cyclic (IgG), highest tertile	2.02	7.51	2.49	22.62
H4 33-48 cit 39 (IgA2), lowest tertile	1.92	6.80	2.54	18.24
H2A/a-2 1-20 (IgA2), highest tertile	1.80	6.03	2.46	14.79
<i>MUC5B</i> promoter variant present	0.06	1.07	0.30	3.82

BMI = body mass index, cit = citrullinated, CRP = C-reactive protein, DAS = disease activity score, h = histone, Ig = immunoglobulin, OR = odds ratio, LCL = lower confidence limit, RA-ILD = rheumatoid arthritis interstitial lung disease, UCL = upper confidence limit